Performance of ⁸⁹Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

• Yvonne W. S. Jauw ,

  * E-mail: yws.jauw@vumc.nl

  Affiliation Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Josée M. Zijlstra,

  Affiliation Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Daphne de Jong,

  Affiliation Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Danielle J. Vugts,

  Affiliation Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Sonja Zweegman,

  Affiliation Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Otto S. Hoekstra,

  Affiliation Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Guus A. M. S. van Dongen,

  Affiliation Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

  ⨯
• Marc C. Huisman

  Affiliation Department of Radiology & Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands

  ⨯